Key facts
- Merck KGaA will acquire Bio-Techne Corp. for $11.3 billion.
- The acquisition offer price for Bio-Techne is $73 per share in cash.
- The offer price includes a 36% premium over Bio-Techne's one-month average share price.
- Volkswagen is selling a majority stake in its marine engine unit, Everllence.
- Bain Capital is acquiring the majority stake in Everllence.
- The sale of Everllence is expected to generate €7.4 billion for Volkswagen.
- Volkswagen shares rose 2.4% following the announcement.
- Merck KGaA is a German science and healthcare firm.
- Bio-Techne Corp. is a biotech company.
- Bain Capital is a U.S. private equity firm.
German science and healthcare company Merck KGaA has announced an agreement to acquire Bio-Techne Corp. for $11.3 billion. The acquisition includes a cash offer of $73 per share, which represents a 36% premium over Bio-Techne's one-month average share price. This strategic move by Merck KGaA is intended to enhance its life science business segment.
In a separate development, Volkswagen is divesting a majority stake in its marine engine unit, Everllence, to the U.S. private equity firm Bain Capital. This transaction is anticipated to yield approximately €7.4 billion for the German automaker. Following the announcement of this deal, Volkswagen's shares experienced an increase of 2.4% in trading.